Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL922401 | 0.83 | FFAR1 (0.51) | FFAR1ARHPGDALDH1A1GAA | |
| SCHEMBL5110412 | 0.83 | ALDH1A1 (0.53) | TTRARALDH1A1MEN1KMT2A | |
| SCHEMBL1745426 | 0.83 | FFAR1 (0.52) | FFAR1TTRNR1H2NR1H3AR | |
| SCHEMBL5112773 | 0.81 | TTR (0.65) | TTRARGAALTA4HTSHR | |
| SCHEMBL1746823 | 0.81 | LTA4H (0.60) | FFAR1TTRHPGDLPAR1LPAR5 | |
| SCHEMBL2354368 | 0.80 | TTR (0.50) | TTRLPAR1LPAR5F10LTA4H | |
| SCHEMBL13452511 | 0.80 | GAA (0.58) | TTRHPGDALDH1A1GAAF10 | |
| SCHEMBL11489016 | 0.80 | TTR (0.50) | TTRALDH1A1GAALTA4HMEN1 | |
| SCHEMBL11163285 | 0.80 | TTR (0.50) | TTRNR1H2NR1H3ARHPGD | |
| SCHEMBL2349289 | 0.80 | TTR (0.46) | TTRARALDH1A1LTA4HMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856278-B2 | Lysophosphatidylserine derivative | THE UNIVERSITY OF TOKYO (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | THE UNIVERSITY OF TOKYO (JP) | 2017-07-27 | — | — | US | disclosed |
| WO-2016002948-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | 国立大学法人東京大学 | 2016-01-07 | — | — | WO | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | FFAR1 16/4885TTR 4393/4885NR1H2 75/4885 |
| US-20170210767-A1 | LYSOPHOSPHATIDYLSERINE DERIVATIVE | LPAR3, LPAR1, LPAR4 | FFAR1 84/4885TTR 4333/4885NR1H2 168/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | FFAR1 33/4885TTR 4688/4885NR1H2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.